Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab plus platinum-etoposide versus chemotherapy alone in limited-stage small-cell lung cancer
ChiCTR2400083366Phase 2Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab, carboplatin, cisplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Pathologic complete response rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
tislelizumabcarboplatincisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400083366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083366.